DrugPatentWatch Database Preview
Peramivir - Generic Drug Details
» See Plans and Pricing
What are the generic sources for peramivir and what is the scope of patent protection?
Peramivir
is the generic ingredient in one branded drug marketed by Biocryst and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.Peramivir has sixty-one patent family members in twenty-eight countries.
There is one drug master file entry for peramivir. One supplier is listed for this compound.
Summary for peramivir
International Patents: | 61 |
US Patents: | 3 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Drug Master File Entries: | 1 |
Suppliers / Packagers: | 1 |
Bulk Api Vendors: | 109 |
Clinical Trials: | 15 |
Patent Applications: | 852 |
DailyMed Link: | peramivir at DailyMed |
Recent Clinical Trials for peramivir
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Hoffmann-La Roche | Phase 3 |
Department of Health and Human Services | Phase 4 |
Johns Hopkins University | Phase 4 |
US Patents and Regulatory Information for peramivir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for peramivir
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | Start Trial | Start Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for peramivir
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2007095218 | Start Trial |
South Korea | 20160129105 | Start Trial |
China | 1282316 | Start Trial |
Cyprus | 1109153 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |